IBDEI0VG ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15553,1,3,0)
 ;;=3^289.9
 ;;^UTILITY(U,$J,358.3,15553,1,4,0)
 ;;=4^THROMBOCYTOSIS
 ;;^UTILITY(U,$J,358.3,15553,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,15554,0)
 ;;=401.9^^95^947^1
 ;;^UTILITY(U,$J,358.3,15554,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15554,1,3,0)
 ;;=3^401.9
 ;;^UTILITY(U,$J,358.3,15554,1,4,0)
 ;;=4^HYPERTENSION NOS
 ;;^UTILITY(U,$J,358.3,15554,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,15555,0)
 ;;=401.1^^95^947^3
 ;;^UTILITY(U,$J,358.3,15555,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15555,1,3,0)
 ;;=3^401.1
 ;;^UTILITY(U,$J,358.3,15555,1,4,0)
 ;;=4^HYPERTENSION,BENIGN
 ;;^UTILITY(U,$J,358.3,15555,2)
 ;;=^269591
 ;;^UTILITY(U,$J,358.3,15556,0)
 ;;=401.0^^95^947^2
 ;;^UTILITY(U,$J,358.3,15556,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15556,1,3,0)
 ;;=3^401.0
 ;;^UTILITY(U,$J,358.3,15556,1,4,0)
 ;;=4^HYPERTENSION,ACCELERATED
 ;;^UTILITY(U,$J,358.3,15556,2)
 ;;=^73505
 ;;^UTILITY(U,$J,358.3,15557,0)
 ;;=227.0^^95^948^1
 ;;^UTILITY(U,$J,358.3,15557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15557,1,3,0)
 ;;=3^227.0
 ;;^UTILITY(U,$J,358.3,15557,1,4,0)
 ;;=4^ADRENAL NEOPLASM,BENIGN
 ;;^UTILITY(U,$J,358.3,15557,2)
 ;;=^267688
 ;;^UTILITY(U,$J,358.3,15558,0)
 ;;=194.0^^95^948^2
 ;;^UTILITY(U,$J,358.3,15558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15558,1,3,0)
 ;;=3^194.0
 ;;^UTILITY(U,$J,358.3,15558,1,4,0)
 ;;=4^ADRENAL NEOPLASM,MALIGNANT
 ;;^UTILITY(U,$J,358.3,15558,2)
 ;;=^267298
 ;;^UTILITY(U,$J,358.3,15559,0)
 ;;=255.10^^95^948^3
 ;;^UTILITY(U,$J,358.3,15559,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15559,1,3,0)
 ;;=3^255.10
 ;;^UTILITY(U,$J,358.3,15559,1,4,0)
 ;;=4^ALDOSTERONISM
 ;;^UTILITY(U,$J,358.3,15559,2)
 ;;=^330019
 ;;^UTILITY(U,$J,358.3,15560,0)
 ;;=255.0^^95^948^4
 ;;^UTILITY(U,$J,358.3,15560,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15560,1,3,0)
 ;;=3^255.0
 ;;^UTILITY(U,$J,358.3,15560,1,4,0)
 ;;=4^CUSHING'S SYNDROME
 ;;^UTILITY(U,$J,358.3,15560,2)
 ;;=^29802
 ;;^UTILITY(U,$J,358.3,15561,0)
 ;;=403.90^^95^948^6
 ;;^UTILITY(U,$J,358.3,15561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15561,1,3,0)
 ;;=3^403.90
 ;;^UTILITY(U,$J,358.3,15561,1,4,0)
 ;;=4^HTN RENAL W/O RENAL FAILURE NOS
 ;;^UTILITY(U,$J,358.3,15561,2)
 ;;=^334272
 ;;^UTILITY(U,$J,358.3,15562,0)
 ;;=403.91^^95^948^5
 ;;^UTILITY(U,$J,358.3,15562,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15562,1,3,0)
 ;;=3^403.91
 ;;^UTILITY(U,$J,358.3,15562,1,4,0)
 ;;=4^HTN RENAL W/ RENAL FAILURE NOS
 ;;^UTILITY(U,$J,358.3,15562,2)
 ;;=^334242
 ;;^UTILITY(U,$J,358.3,15563,0)
 ;;=405.91^^95^948^7
 ;;^UTILITY(U,$J,358.3,15563,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15563,1,3,0)
 ;;=3^405.91
 ;;^UTILITY(U,$J,358.3,15563,1,4,0)
 ;;=4^HTN RENOVASCULAR NOS
 ;;^UTILITY(U,$J,358.3,15563,2)
 ;;=^269634
 ;;^UTILITY(U,$J,358.3,15564,0)
 ;;=403.00^^95^948^9
 ;;^UTILITY(U,$J,358.3,15564,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15564,1,3,0)
 ;;=3^403.00
 ;;^UTILITY(U,$J,358.3,15564,1,4,0)
 ;;=4^MAL HTN RENAL W/O RENAL FAILURE
 ;;^UTILITY(U,$J,358.3,15564,2)
 ;;=^334270
 ;;^UTILITY(U,$J,358.3,15565,0)
 ;;=403.01^^95^948^8
 ;;^UTILITY(U,$J,358.3,15565,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15565,1,3,0)
 ;;=3^403.01
 ;;^UTILITY(U,$J,358.3,15565,1,4,0)
 ;;=4^MAL HTN RENAL W/ RENAL FAILURE
 ;;^UTILITY(U,$J,358.3,15565,2)
 ;;=^334240
 ;;^UTILITY(U,$J,358.3,15566,0)
 ;;=405.01^^95^948^10
 ;;^UTILITY(U,$J,358.3,15566,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15566,1,3,0)
 ;;=3^405.01
 ;;^UTILITY(U,$J,358.3,15566,1,4,0)
 ;;=4^MAL HTN RENOVASCULAR
 ;;^UTILITY(U,$J,358.3,15566,2)
 ;;=^269628
 ;;^UTILITY(U,$J,358.3,15567,0)
 ;;=404.91^^95^949^1
